Wednesday, November 7, 2007

AHA - 2007: Hypertension Vaccine Safe, Well-Tolerated in Phase 2a Study

American Heart Association Scientific Sessions 2007: Abstract 2519. Presented November 6, 2007

Hypertension Vaccine Safe, Well-Tolerated in Phase 2a Study

Medscape Medical News 2007. © 2007 Medscape

November 6, 2007 (Orlando) — Results of a phase 2 study suggest that an investigational vaccine against angiotensin II was safe and well tolerated in patients with mild to moderate hypertension. The vaccine produced a long-lived antibody response with a half-life of about 4 months.

"Treatment with the high dose produced a significant reduction of daytime ambulatory blood pressure [BP] and a marked reduction in the early morning hours, when most adverse cardiovascular events occur," study author Jürg Nussberger, MD, from Centre Hospitalier Université Vaudois, in Lausanne, Switzerland, told attendees at the American Heart Association 2007 Scientific Sessions here.

"Future studies will apply state-of-the-art formulations and treatment regimens to explore the full potential of this approach," he said.

No comments: